Compassionate use of ruxolitinib in patients with SARS‐Cov‐2 infection not on mechanical ventilation: Short‐term effects on inflammation and ventilation

Autor: Giovanbattista Ippoliti, Gianluca Perseghin, Simone Mazzetti, Paolo Grosso, Andrea Mortara, Francesco Catagnano, Pietro Delfino, Davide Margonato, Chiara Bersano, Marinella Lauriola
Přispěvatelé: Mortara, A, Mazzetti, S, Margonato, D, Delfino, P, Bersano, C, Catagnano, F, Lauriola, M, Grosso, P, Perseghin, G, Ippoliti, G
Rok vydání: 2021
Předmět:
pandemic infection
Compassionate Use Trials
Male
Ruxolitinib
ruxolitinib
medicine.medical_treatment
Anti-Inflammatory Agents
Gastroenterology
Medicine
General Pharmacology
Toxicology and Pharmaceutics
Respiratory system
Oxygen saturation (medicine)
Sars-Covid-2
Aged
80 and over
treatment
ventilation
Respiration
General Neuroscience
Articles
General Medicine
Middle Aged
JAK inhibitor
Breathing
Female
Public aspects of medicine
RA1-1270
medicine.symptom
medicine.drug
Adult
medicine.medical_specialty
Inflammation
RM1-950
Article
General Biochemistry
Genetics and Molecular Biology
Immune system
Internal medicine
Nitriles
Humans
Janus Kinase Inhibitors
MED/13 - ENDOCRINOLOGIA
Adverse effect
Aged
Mechanical ventilation
SARS-CoV-2
business.industry
Research
COVID-19
Respiration
Artificial
COVID-19 Drug Treatment
Pyrimidines
inflammation
Pyrazoles
Therapeutics. Pharmacology
business
Zdroj: Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 3, Pp 1062-1068 (2021)
ISSN: 1752-8062
1752-8054
DOI: 10.1111/cts.12971
Popis: Ruxolitinib is an anti-inflammatory drug that inhibits the Janus kinase-signal transducer (JAK-STAT) pathway on the surface of immune cells. The potential targeting of this pathway using JAK inhibitors is a promising approach in patients affected by coronavirus disease 2019 (COVID-19). Ruxolitinib was provided as a compassionate use in patients consecutively admitted to our institution for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. Inclusion criteria were oxygen saturation less than or equal to 92%, signs of interstitial pneumonia, and no need of mechanical ventilation. Patients received 5mg b.i.d. of ruxolitinib for 15days, data were collected at baseline and on days 4, 7, and 15 during treatment. Two main targets were identified, C-reactive protein (CRP) and PaO2/FiO2 ratio. In the 31 patients who received ruxolitinib, symptoms improved (dyspnea scale) on day 7 in 25 of 31 patients (80.6%); CRP decreased progressively from baseline (79.1±73.4mg/dl) to day 15 (18.6±33.2, p=0.022). In parallel with CRP, PO2/FiO2 ratio increased progressively during the 3 steps from 183±95 to 361±144mmHg (p 
Databáze: OpenAIRE
Externí odkaz: